All hinges on AZ here. If AZ don't support this, rest of the pharma business may have second thoughts. Good that 2 further large pharma companies want to test it though and pay for all the costs associated with that. They must think it worthwhile trialing, so that is positive. Next quarter will be significant
Ann: Strategy Update, page-2
Add LBT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
1.7¢ |
Change
0.000(0.00%) |
Mkt cap ! $33.23M | |||
| Open | High | Low | Value | Volume |
| 1.8¢ | 1.9¢ | 1.7¢ | $33.77K | 1.921M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 1408000 | 1.6¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.8¢ | 818258 | 3 |
View Market Depth
| Last trade - 11.25am 02/10/2024 (20 minute delay) ? |
| LBT (ASX) Chart |